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Abstract
The natural history of hepatocellular carcinoma (HCC) 
with portal vein tumor thrombosis (PVTT) is dismal 
(approximately 2-4 mo), and PVTT is reportedly 
found in 10%-40% of HCC patients at diagnosis. 
According to the Barcelona Clinic Liver Cancer 
(BCLC) Staging System (which is the most widely 
adopted HCC management guideline), sorafenib is 
the standard of care for advanced HCC (i.e. , BCLC 
stage C) and the presence of PVTT is included in 
this category. However, sorafenib treatment only 
marginally prolongs patient survival and, notably, its 
therapeutic efficacy is reduced in patients with PVTT. 
In this context, there have been diverse efforts to 
develop alternatives to current standard systemic 
chemotherapies or combination treatment options. To 
date, many studies on transarterial chemoembolization, 
3-dimensional conformal radiotherapy, hepatic arterial 
chemotherapy, and transarterial radioembolization 
report better overall survival than sorafenib therapy 
alone, but their outcomes need to be verified in future 
prospective, randomized controlled studies in order 
to be incorporated into current treatment guidelines. 
Additionally, combination strategies have been applied 
to treat HCC patients with PVTT, with the hope that the 
possible synergistic actions among different treatment 
modalities would provide promising results. This 
narrative review describes the current status of the 
management options for HCC with PVTT, with a focus 
on overall survival.
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Core tip: Hepatocellular carcinoma (HCC) with portal 
vein tumor thrombosis (PVTT) is associated with a 
grave prognosis if left untreated. Sorafenib is the only 
treatment modality recommended for treating HCC 
patients with PVTT according to most international HCC 
treatment guidelines. However, the survival benefits 
observed following systemic sorafenib treatment are 
only marginal. Under these circumstances, the need 
for better treatment options remains unfulfilled. In this 
comprehensive review, various treatment options are 
presented-including transarterial chemoembolization, 
transarterial radioembolization, hepatic arterial infusion, 
chemotherapy, and radiotherapy-and their outcomes, 
along with combination strategies.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common 
primary liver malignancy and the world’s fifth most 
common cancer, and predominantly occurs in patients 
with liver cirrhosis[1]. Portal vein tumor thrombosis 
(PVTT) is reportedly found in 10%-40% of HCC 
patients at diagnosis[2-4]. PVTT is associated with a 
dismal prognosis, as it is closely related to intrahepatic 
metastasis and tumor recurrence, and patients only 
demonstrate 2-4 mo of overall survival with the best 
supportive care[3-5].
In HCC patients with PVTT, the management 
options are limited and the optimal treatments remain 
largely controversial. Curative-intent surgery is often 
technically challenging, and liver transplant is mostly 
contraindicated due to high tumor recurrence rates[6,7]. 
Transarterial chemoembolization (TACE) is generally 
contraindicated as it can subsequently induce hepatic 
necrosis and worsen liver function. Radiofrequency 
ablation is not effective or safe due to the proximity of 
the hepatic vasculature. External beam radiation plays 
a limited role in PVTT due to the sensitivity of the liver 
to radiation and potential for liver failure.
The Barcelona Clinic Liver Cancer (BCLC) Staging 
System is the most widely adopted HCC manage-
ment guideline, which classifies HCC with PVTT as 
advanced HCC (BCLC stage C)[8]. According to the 
BCLC guidelines, sorafenib is the standard of care 
for patients with advanced HCC (Figure 1). However, 
the survival benefits observed following sorafenib 
treatment are limited, and this underscores the need 
for better treatment strategies[9]. In recent years, 
there have been attempts to develop alternative 
or combination treatments in order to improve the 
overall survival of patients with HCC and PVTT. In this 
narrative article, these diverse treatment modalities 
are thoroughly reviewed (Table 1).
SYSTEMIC THERAPY
Sorafenib-an oral multi-kinase tyrosine inhibitor that 
demonstrates antiproliferative and antiangiogenic 
effects-is the only drug proven to improve overall 
survival in patients with advanced HCC, including 
those with PVTT[10]. The SHARP trial reported better 
median overall survival without significant drug 
toxicity in sorafenib-treated patients (10.7 mo in the 
sorafenib group vs 7.9 mo in placebo group; HR = 
0.69; 95%CI: 0.55-0.87, p < 0.001)[9]. Subsequent 
subgroup analyses revealed that sorafenib consistently 
improved the median overall survival (OS) and median 
time to tumor progression (TTP) in comparison with 
the control group, irrespective of disease etiology, 
baseline tumor extent (e.g., presence of macroscopic 
vascular invasion), tumor stage (BCLC B-C), prior 
therapy, or performance status. In particular, patients 
with macrovascular invasion who were treated with 
sorafenib demonstrated a longer median OS (8.1 mo 
vs 4.9 mo) and TTP (4.1 mo vs 2.7 mo)[10]. Similar 
findings were also identified in an Asian-Pacific 
population (6.5 mo in the sorafenib group vs 4.2 mo 
in the placebo group; HR = 0.68; 95%CI: 0.50-0.93; 
p = 0.014)[9,11]. Regarding the safety profile, the most 
common adverse events included diarrhea, hand-foot 
skin reaction, fatigue, and skin rash. However, the 
incidence of serious or life-threatening complications 
was rare and not affected by the baseline patient 
characteristics. Therefore, it was suggested that 
sorafenib could be administered to a wide range of 
patients with HCC[10]. Since these 2 key studies were 
released, sorafenib has been considered the standard 
of care for HCC patients with PVTT by many treatment 
guidelines such as BCLC Staging System, European 
Association for the Study of Liver Disease (EASL), and 
American Association for the Study of Liver Diseases 
(AASLD)[8,12]. A retrospective study of 30 HCC patients 
with PVTT demonstrated that the median OS was 
3.1 mo and the disease control rate was 33.3%, 
respectively[13]. Dose reduction was required in 13 
patients due to fatigue, hand-foot syndrome, diarrhea, 
nausea, and skin rash, but no grade 4 adverse events 
occurred. Interestingly, 3 patients with a partial 
response achieved marked PVTT revascularization, 
and responsive patients demonstrated a significantly 
prolonged OS in comparison with nonresponders. 
It is assumed that sorafenib exerts antithrombotic 
effects on PVTT by inhibiting the vascular endothelial 
growth factor (VEGF) receptor pathway. Therefore, 
a sensitivity analysis is warranted in order to predict 
good responders to Sorafenib treatment.
Unfortunately, the observed survival benefits of 
sorafenib in HCC patients with PVTT are modest, and 
in recent years there have been efforts to combine 
systemic chemotherapy with other locoregional 
therapies in order to improve treatment outcomes. 
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In addition, there are several other systemic agents 
under development, but none have demonstrated 
improved OS. 
TRANSARTERIAL CHEMOEMBOLIZATION 
Transarterial chemoembolization (TACE) refers to the 
percutaneous intraarterial introduction of an embolic 
agent that occludes tumor feeders in combination 
with an anticancer agent, with the aim of delivering 
sustained drug levels to the HCC. The anticancer agent 
is mixed with Lipiodol or loaded onto microspheres. 
Until now, TACE has been widely used to treat HCC in 
different stages and plays an established role in the 
treatment of unresectable HCC[14-18]. In the presence 
of PVTT, however, TACE is theoretically contraindicated 
because of the potential risk of hepatic insufficiency 
that results from ischemia following TACE. However, 
recent studies demonstrate that TACE can be safely 
performed in the presence of adequate collateral 
circulation around the occluded portal vein[19,20]. 
Chung et al[21] have investigated the efficacy and 
safety of TACE in patients with HCC and main PVTT 
and reported a median OS period of 3.7 mo. The 
median survival of the TACE group was significantly 
longer than the supportive care group (5.6 mo 
vs 2.2 mo). TACE and Child-Pugh A classification 
were independent predictive factors associated with 
better overall survival. Regarding complications, no 
procedure-related deaths were reported within 4 wk 
after TACE, and morbidity was 28.9%. A prospective 
comparative study investigated the efficacy and safety 
of administering TACE to HCC patients with PVTT in 
comparison with conservative management[22]. In 
that study, the TACE group demonstrated significantly 
better OS than the conservative treatment group 
(7.1 mo vs 4.1 mo), and TACE-related complications 
were adequately managed using conservative 
treatment. According to the subgroup analysis of 
segmental and major PVTT, the TACE group also 
demonstrated significantly better survival. Treatment 
type, PVTT extent, tumor size, and serum bilirubin 
were independent prognostic factors of survival 
on multivariate analysis. A recent meta-analysis, 
which included the aforementioned study, showed 
that patients who underwent a TACE procedure 
demonstrated a significantly better 1-year survival rate 
in comparison with patients who received conservative 
treatment (OR = 3.079; 95%CI: 1.094-8.662)[23].
As an alternative to conventional lipiodol-based 
TACE, nonresorbable microspheres can be loaded 
with an anticancer agent and intraarterially infused 
to increase the local drug concentration and reduce 
systemic toxicity[24]. These particles are known as 
drug-eluting beads (DEB). There are few studies on 
using DEB-TACE to treat HCC and PVTT. Kalva et al[25] 
evaluated the safety and efficacy of administering 
DEB-TACE to advanced HCC patients, including those 
with lobar PVTT. The median OS was 13.3 mo, and the 
presence of portal vein thrombosis demonstrated no 
statistically significant association with OS. 
As demonstrated by various studies, TACE is 
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Figure 1  Updated barcelona clinic liver cancer staging system and treatment strategy. HCC: Hepatocellular carcinoma; RT: Radiation therapy. 
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randomized controlled trials. To become an alternative 
to current Sorafenib treatment, the better outcomes 
observed in previous retrospective studies using HAIC 
need to be verified by future prospective studies and 
validated in a Western population.
EXTERNAL BEAM RADIATION
The role of external beam radiation therapy (RT) for 
HCC is limited due to the risks of radiation-induced 
liver disease and the low tolerance of the whole liver 
to RT[33]. However, rapid advances in radiotherapy 
techniques, including 3-dimensional conformal 
radiotherapy and image-guided radiotherapy, as well 
as knowledge on partial volume liver tolerance, have 
enabled the delivery of higher radiation doses to HCC 
than in the past, thereby allowing RT to be used as a 
potential standalone or adjunct treatment for HCC[34-36].
Notably, one of the primary indications for RT is the 
presence of PVTT, and previous studies report good 
treatment responses and promising outcomes using 
RT[37,38]. A retrospective study evaluated the treatment 
outcomes of RT in 38 patients with HCC with PVTT[39]. 
In that study, the treatment rate was 44.7% and OS 
was 9.6 mo. Nakazawa et al[40] recently compared 
standard sorafenib therapy to RT in patients with 
unresectable HCC with main or first-branch PVTT, and 
they reported a longer median OS in the RT group 
(10.9 mo vs 4.8 mo, p = 0.025) after performing 
propensity score analysis (28 pairs). In their study, 
whereas almost half the patients discontinued 
sorafenib due to adverse events, there was no grade 
3 or higher gastrointestinal or hepatic toxicity and 
grade 3 leukocytopenia was only observed in 1 patient 
in the RT group. Because HAIC is not regarded as a 
standard therapeutic modality, future large-scale and 
prospective studies are warranted in order to test the 
clinical efficacy and safety of using RT to treat HCC 
with PVTT.
TRANSARTERIAL RADIOEMBOLIZATION
Transarterial radioembolization (TARE) and selective 
considered safe and feasible for select patients with 
unresectable HCC, PVTT, and preserved liver function 
and collateral portal venous circulation. However, to 
date, the reported OS period for HCC patients with 
PVTT who receive TACE is slightly better than that of 
patients who receive sorafenib therapy, though this 
claim needs to be validated in a prospective study.
HEPATIC ARTERIAL INFUSION 
CHEMOTHERAPY
Hepatic arterial infusion chemotherapy (HAIC) using 
an implantable port system has been applied to treat 
advanced HCC with PVTT. HAIC is theoretically more 
effective against HCC than systemic chemotherapy 
because it provides the direct delivery of a high 
concentration of the anticancer agent to the tumor 
through the hepatic artery. HAIC also minimizes 
systemic toxicities due to first-pass effects[26]. HAIC 
is usually administered using 1 of the following 3 
well-reported regimens: cisplatin alone, 5-FU plus 
cisplatin, or 5-FU plus interferon. Many studies have 
been conducted on advanced HCC with PVTT and 
demonstrate a median OS of 6.5-14 mo[26-29]. Quite 
recently, Song et al[30] conducted a multicenter study 
to compare the efficacy of sorafenib with HAIC in HCC 
patients with PVTT. In their study, the median OS (7.1 
mo vs 5.5 mo, p = 0.011) and TTP were significantly 
longer in the HAIC group than in the sorafenib group 
(3.3 mo vs 2.2 mo, p = 0.034). 
Regarding the safety profile of HAIC, hemato-
logic complications (e.g., anemia, neutropenia, 
thrombocytopenia) and gastrointestinal toxicity (e.g., 
nausea, vomiting, abdominal pain) can occur. Most 
HAIC-related toxicities are transient, tolerable, and 
successfully controlled with conservative treatment, 
although some patients end up withdrawing from HAIC 
therapy. In addition, catheter-related complications 
(e.g., hematoma, catheter occlusion, infection) can 
also occur[31,32]. However, HAIC is not recommended as 
a standard treatment for HCC patients with PVTT, as 
these data are mostly from Japan and there is a lack of 
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Table 1  Summary of combination treatments for hepatocellular carcinoma patients with portal vein tumor thrombosis
Overall survival 
(mo)
Extent of PVTT (mo) Ref.
Main PVTT Branch PVTT
BSC 2-4 Llovet et al[3], Schöniger-Hekele et al[5]
Sorafenib 6.5-8.1 Llovet et al[9], Cheng et al[11]
TACE 7-10      5.3 10 Chung et al[21], Luo et al[22]
HAIC 6.5-14 Park et al[26], Ando et al[27], Eun et al[28]
RT 9.6-10.9 Toya et al[39], Nakazawa et al[40]
TARE 6-16.9      7.7    16.9 Salem et al[47], Kulik et al[49], Sangro et al[48], Memon et al[50]
TACE plus sorafenib 11-13   3 13-15 Pan et al[58], Zhu et al[59]
Sorafenib plus RT 8.6-10.6 Chen et al[53], Chow et al[61]
TACE plus RT 10.6-12 12 Yoon et al[64], Chung et al[72], Kim et al[73]
HAIC plus RT 12.1 Fujino et al[76]
BSC: Best supportive care; TACE: Transarterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; RT: Radiation therapy; TARE: 
Transarterial radioembolization; PVTT: Portal vein thrombosis.
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internal radiation therapy (SIRT) using beta-emitting 
yittrium-90 in resin microspheres or glass particles 
have been introduced as alternatives to TACE for 
HCC[41]. TARE differs from TACE in that it offers 
antitumor effects in the form of local beta radiation, 
not arterial obstruction. The embolic materials 
are loaded with yittrium-90 and administered via 
intraarterial injection, which allows lobar, segmental, 
and subsegmental therapy. The average penetration 
depth by this local radiation into the liver tissue is 
approximately 2.5 mm, thus sparing the normal 
adjacent liver from damage and obviating the need 
of postprocedure isolation. The half-life is 64 h, and 
almost the entire radiation dose is delivered within 
14 d of the procedure[42-44]. There is some evidence 
that TARE results in encouraging outcomes, especially 
in patients with PVTT which is a contraindication 
to TACE[8,45,46]. Administering TARE to patients with 
advanced HCC has demonstrated a median OS of 6-10 
mo, which is comparable to the 6.5-10.7 mo reported 
in landmark studies on sorafenib[9,11]. Because it 
produces much fewer embolic effects than TACE, PVTT 
is not a contraindication for TARE, but the presence 
and extent of PVTT does affect prognosis. Salem et 
al[47] studied the long-term outcomes of using TARE 
to treat HCC and reported a median OS of 16.6 mo in 
Child-Pugh A patients with branch PVTT vs 6.5 mo in 
Child-Pugh B patients. Among patients with main PVTT, 
the median OS decreased to 7.7 mo in Child-Pugh A 
patients and 4.5 mo in Child-Pugh B patients. Smaller 
studies using TARE report concordant results. When 
the distinction between main and branch PVTT was 
made, the median survival periods reported by Sangro 
et al[48] were 9.7 and 10.7 mo, and those reported 
by Kulik et al[49] were 4.4 and 9.9 mo. Memon et 
al[50] reported even higher median survival periods of 
15.7 and 9 mo in Child-Pugh A patients, respectively. 
Mazzaferro et al[51] performed a single-center, pros-
pective, phase Ⅱ trial to study the efficacy of TACE on 
HCC patients with PVTT. They reported a median OS 
of 13 mo in 35 HCC patients with branch or main PVTT 
and better patient survival in Child-Pugh A patients 
(16 mo vs 6 mo). In a recent retrospective study, 
Gramenzi et al[52] compared the outcomes of sorafenib 
and TARE in patients with advanced HCC. The median 
OS values of the 2 groups were comparable: 13.2 mo 
in the TARE group (63 patients) and 14.4 mo in the 
sorafenib group (74 patients). Following propensity 
score analysis (38 pairs), the median OS did not differ 
between groups. Ongoing randomized controlled trials 
that compare standard sorafenib therapy to TARE 
as a first- or second-line treatment for HCC patients 
with PVTT are expected to define the populations that 
benefit from this therapeutic modality.
TARE is generally well tolerated, and the most 
common complication is postembolization syndrome 
which occurs in 20%-55% of patients. Postembolization 
syndrome consists of various symptoms (e.g., fatigue, 
fever, nausea, vomiting, abdominal pain), which are 
usually well-tolerated with conservative management. 
Other reported complications, such as radiation-
induced liver disease, radiation pneumonitis, radiation 
cholecystitis, biloma, hepatic abscess, and biliary 
stricture, are uncommon[47,49]. TARE can lead to severe 
adverse events, such as gastrointestinal ulcerations, 
in < 5% of patients[53,54]. However, gastrointestinal 
toxicities may be prevented by carefully administering 
preemptive coil embolization. 
EMERGENCE OF COMBINATION 
STRATEGIES FOR TREATING HCC WITH 
PVTT
As mentioned earlier, the current standard sorafenib 
treatment only provides modest survival benefits, and, 
thus, investigators have made concerted efforts to 
combine different modalities, which will be discussed in 
the following sections. 
TACE IN COMBINATION WITH 
SORAFENIB
The efficacy of sorafenib in combination with TACE 
has been investigated, as these two therapeutic 
options are expected to work synergistically. TACE-
induced hypoxia in surviving tumor cells results 
in the release of angiogenic growth factors, which 
contribute to tumor recurrence, metastasis, and 
worse outcomes[55,56]. Sorafenib suppresses tumor 
cell proliferation by exerting antiangiogenic effects 
through the blocking of VEGF receptor-2 and -3 
and platelet-derived growth factor receptor tyrosine 
kinase[57]. A retrospective study on combining TACE 
and sorafenib to treat HCC patients with PVTT (branch 
and main PVTT) demonstrated a median OS of 13 mo 
and median TTP of 7 mo, respectively[58]. Procedure-
related mortality and grade 4 adverse events did not 
occur. Child-Pugh class, extrahepatic metastasis, and 
gross morphologic type were prognostic factors. Zhu 
et al[59] compared the outcomes of sorafenib plus 
TACE to the outcomes of TACE alone in patients with 
HCC and PVTT. TACE plus sorafenib demonstrated 
significant survival benefits in comparison with TACE 
alone (11 mo vs 6 mo, p < 0.001). When considering 
first-, second-, and lower-order branch PVTT, subgroup 
analyses of OS in patients with different types of PVTT 
revealed that the median OS of patients treated with 
TACE plus sorafenib is significantly longer than that 
of patients treated with TACE alone (13 mo vs 6 mo 
for patients with first-order PVTT; 15 mo vs 10 mo for 
patients with second- or lower-order PVTT). In patients 
with main PVTT, no survival benefit was observed 
between groups (3 mo in both groups). The worsening 
of liver function after TACE-sorafenib treatment was 
only noted in patients with main PVTT, and sorafenib-
related complications classified as grade 3 or higher 
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occurred in 16 patients (35%). 
A phase Ⅱ prospective trial (START trial) is under 
way in which the efficacy of TACE plus sorafenib when 
administered to HCC patients (including those with 
branch PVTT) will be investigated. Interim analysis has 
indicated promising outcomes and acceptable adverse 
event rates, and, thus, it is expected that the role of 
combination therapy in HCC patients with PVTT will be 
determined within the foreseeable future.
SORAFENIB PLUS RADIOTHERAPY
The combination of sorafenib and radiotherapy is 
based on the finding that sorafenib enhances the 
radiosensitivity of human HCC cell lines by selectively 
inhibiting the radiation-induced activation of the 
VEGFR2 and extracellular signal-regulated kinase 
(ERK) pathways, thereby promoting radiation-
induced apoptosis[60]. In this context, the concurrent 
administration of sorafenib and radiotherapy-in the 
form of either TARE or external beam radiation-is 
expected to work synergistically on advanced HCC. In 
a phase Ⅱ study on combining sorafenib and external 
beam radiation therapy, the mean OS was 10.6 mo 
in Child-Pugh A patients with PVTT. Of the 40 patients 
analyzed, 4 (10%) and 6 patients (15%) experienced 
grade 3 or higher hepatic toxicities during or before 
RT, respectively. Therefore, special care needs to be 
taken when combination therapy is considered[53]. 
Combination of sorafenib and TARE therapy is 
reportedly well-tolerated, and the mean OS was 
reported to be 8.6 mo in advanced HCC patients[61]. 
However, that study only included patients with branch 
PVTT, not major PVTT. In a recent prospective study 
on the safety profile of combination TARE-sorafenib 
treatment, the incidences of total and > grade 3 
adverse events did not statistically differ between the 
combination treatment and sorafenib-alone groups[62]. 
TACE PLUS RADIOTHERAPY
TACE in combination with radiotherapy is a newly 
introduced combination strategy that results in 
improved outcomes in HCC patients with PVTT[38,39,63-70]. 
The rationale behind this combined treatment is 
that reducing PVTT with radiotherapy may inhibit 
intravascular tumor growth and preserve adequate 
portal venous flow, thereby preventing the deterioration 
of liver function, limiting intrahepatic tumor spread, 
and facilitating subsequent treatments for the primary 
tumor[66,68]. In addition, radiotherapy may potentially 
increase the effects of subsequent chemoembolization 
by inducing the regression of the arterioportal shunt 
around the PVTT[71].
In a recent retrospective study, Chung et al[72] 
evaluated the safety and survival outcomes of TACE 
plus radiotherapy in patients with HCC invading the 
main portal vein. After chemoembolization, major 
complications occurred in 30 of 151 patients (19.9%) 
and were more frequently seen in Child-Pugh B 
patients. The 30-d mortality rate was 0.7%, and 
most adverse events were managed by conservative 
treatment. In addition, adjuvant RT for main PVTT 
after chemoembolization in 147 patients was 
uneventful without RT-associated adverse events. 
The median OS period was 12 mo (14 mo in Child-
Pugh class A patients vs 8 mo in Child-Pugh class 
B patients). Yoon et al[64] also studied the efficacy 
of TACE in combination with RT for HCC with PVTT 
(main or bilateral/unilateral) and reported a 28.1% 
tumor response rate and OS of 10.6 mo. Kim et al[73] 
compared the efficacy of TACE with or without RT vs 
sorafenib for advanced HCC with PVTT. In that study, 
patients were divided into 3 different treatment pairs 
(TACE vs TACE + RT; TACE vs sorafenib; and TACE + 
RT vs sorafenib). According to the propensity score 
matched analysis, the group that received TACE in 
combination with radiotherapy demonstrated longer 
TTP and OS values than the groups that received TACE 
alone (102 pairs; 8.7 mo vs 3.6 mo, p < 0.01; 11.4 
mo vs 7.4 mo, p = 0.023, respectively) or sorafenib-
alone groups (30 pairs; 3.4 mo vs 1.8 mo, p < 0.01; 5.9 
mo vs 4.4 mo, p = 0.03, respectively). Although these 
outcomes need to be verified by future randomized 
studies, TACE in combination with radiotherapy could 
serve as an alternative to current standard sorafenib 
therapy. 
HEPATIC ARTERIAL INFUSION AND 
RADIOTHERAPY
Some investigators have combined HAIC with conformal 
radiotherapy to treat HCC patients with PVTT and 
reported the efficacy of arterial infusion chemotherapy 
plus  radiotherapy[74,75]. In a recent retrospective study, 
Fujino et al[76] investigated the efficacy of combination 
therapy for major or first-order branch PVTT and 
reported that the combination group demonstrated a 
significantly longer median OS (12.1 mo vs 7.2 mo) 
and higher objective response rate than the HAIC-
alone group when used to treat intrahepatic HCC 
patients who were nonresponsive to HAIC (objective 
response rate = 56.1% vs 33.3%; median OS = 
8.6 mo vs 5 mo), but no significant differences were 
noted in intrahepatic responders. It is noteworthy that 
reducing PVTT volume with radiotherapy may help 
patients respond better to HAIC. 
OTHER COMBINATION STRATEGIES
Various novel treatment modalities have been developed 
in an effort to reduce PVTT burden. According to 
the BCLC Staging System, radiofrequency ablation 
(RFA) is the standard care for early, stage A HCC. 
Recently, however, it was reported that RFA may 
improve patient survival and has come into use as a 
treatment modality for HCC patients with PVTT[77,78]. 
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TACE in combination with RFA also confers survival 
benefits to PVTT patients[79]. Iodine-125 seeds have 
been used to treat solid tumors, and their use in HCC 
patients with PVTT is reportedly safe and feasible[80]. 
A recent prospective study compared the efficacy and 
safety of TACE in combination with the endovascular 
implantation of an iodine-125 seed strand for PVTT vs 
TACE alone. In that study, TACE in combination with 
iodine-125 seeds demonstrated better median OS than 
TACE alone[81].
GENERAL TREATMENT 
RECOMMENDATIONS FOR HCC WITH 
PVTT
Although the BCLC system, which is based on data from 
randomized controlled studies, has been widely validated, 
it does not reflect the diverse situations that present 
in clinical practice. In particular, because advanced 
HCC (i.e., BCLC C stage) affects heterogeneous 
patient populations, different treatment modalities or 
combination therapies have been advocated in order 
to obtain better treatment outcomes. In HCC patients 
with PVTT, the marginal survival benefits observed with 
sorafenib may be attributed to patient heterogeneity. 
Therefore, subclassification of BCLC stage C patients 
is thought to be the first step to providing more 
individualized treatments to patients with this stage 
of cancer. Under these circumstances, the recently 
introduced Hong Kong Liver Cancer Staging System 
subdivides macrovascular invasion into intrahepatic 
and extrahepatic vascular invasions and recommends 
administering more aggressive treatment to early- and 
intermediate-stage cancers[82]. Regarding the various 
therapeutic modalities reviewed above, it is not easy 
to reach a consensus regarding the best treatment 
options for individual patients and remains an area of 
active discussion because the data on each modality 
reflects regional differences in patient characteristics 
and clinical practice. In particular, the ongoing obser-
vational study (GIDEON) is expected to generate 
better understanding of the effectiveness and safety 
of the diverse treatment options for HCC patients with 
PVTT[83-85].
CONCLUSION
According to the BCLC Staging System, systemic 
therapy using sorafenib is considered the standard 
of care for patients with HCC and PVTT despite its 
modest survival benefits. Other treatment modali-
ties for HCC with PVTT have continued to evolve in 
recent years (e.g., TACE, HAIC, TARE, radiotherapy, 
and various combination strategies), and the BCLC 
recommendations now seem very limiting. However, 
because there are few phase Ⅰ or Ⅱ studies on 
multimodal treatments, it is difficult to validate the 
findings of previous, retrospective, observational 
studies and thus to reach a consensus regarding the 
best options for advanced HCC with PVTT. Therefore, 
future prospective, randomized, controlled studies 
are warranted to compare the outcomes of diverse 
treatment modalities, and the observed findings may 
need to be incorporated into international guidelines.
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